$10.79
3.23%
Nasdaq, Fri, Dec 27 2024
ISIN
US82835W1080
Symbol
SBTX
Sector
Industry

Silverback Therapeutics Stock price

$10.79
-3.74 25.74% 1M
+2.74 34.04% 6M
+5.31 96.90% YTD
+5.15 91.31% 1Y
+4.25 64.98% 3Y
-10.21 48.62% 5Y
-10.21 48.62% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.36 3.23%
ISIN
US82835W1080
Symbol
SBTX
Sector
Industry

Key metrics

Market capitalization $1.05b
Enterprise Value $844.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 328.45
P/S ratio (TTM) P/S ratio 408.03
P/B ratio (TTM) P/B ratio 5.22
Revenue (TTM) Revenue $2.57m
EBIT (operating result TTM) EBIT $-60.51m
Free Cash Flow (TTM) Free Cash Flow $-46.03m
Cash position $204.62m
EPS (TTM) EPS $-0.51
P/E forward negative
P/S forward 126.72
EV/Sales forward 102.01
Short interest 3.95%
Show more

Is Silverback Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Silverback Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Silverback Therapeutics forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Silverback Therapeutics forecast:

Buy
100%

Financial data from Silverback Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2.57 2.57
-
100%
- Direct Costs 0.17 0.17
90% 90%
7%
2.39 2.39
241% 241%
93%
- Selling and Administrative Expenses 43 43
102% 102%
1,668%
- Research and Development Expense 20 20
58% 58%
777%
-60 -60
22% 22%
-2,352%
- Depreciation and Amortization 0.06 0.06
96% 96%
2%
EBIT (Operating Income) EBIT -61 -61
24% 24%
-2,354%
Net Profit -49 -49
42% 42%
-1,911%

In millions USD.

Don't miss a Thing! We will send you all news about Silverback Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Richard Lowenthal
Employees 26
Founded 2015
Website www.ars-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today